References
- G. Papanikolaou and K. Pantopoulos, Iron metabolism and toxicity, Toxicol. Appl. Pharm. 202 (2005) 199-211; DOI: 10.1016/j.taap.2004.06.021.
- E. Beutler, Iron storage disease: Facts, fiction and progress, Blood Cell. Mol. Dis. 39 (2007) 140-147; DOI: 10.1016/j.bcmd.2007.03.009.
- T. B. Chaston, and D. R. Richardson, Iron chelators for the treatment of iron overload disease: Relationship between structure, redox activity, and toxicity, Am. J. Hematol. 73 (2003) 200-210; DOI: 10.1002/ajh.10348.
- H. Boukhalfa and A. L. Crumbliss, Chemical aspects of siderophore mediated iron transport, BioMetals 15 (2002) 325-339; DOI: 10.1023/A:1020218608266.
- J. Matijević-Sosa and Z. Cvetnić, Antimicrobial activity of N-phthaloylamino-hydroxamates, Acta Pharm. 55 (2005) 387-399.
- E. M. F. Muri, M. J. Nieto, R. D. Sindelar and J. S. Williamson, Hydroxamic acids as pharmacological agents, Curr. Med. Chem. 9 (2002) 1631-1653.
- A. Kleeman, J. Engel, B. Kutscher and D. Reichert, Pharmaceutical Substances, Synthesis, Patents, Applications, 4th ed., Thieme Medical Publishers, Stuttgart 2001.
- J. Matijević-Sosa and Lj. Butula, Synthesis and mitodepressive activity of some phthalimidoal-kanehydroxamic acids, Acta Pharm. 43 (1993) 185-194.
- C. A. Burtis and E. R. Ashwood, Clinical Chemistry in Original Papers for Olympus AU 640 Reagents, WB Saunders Company, Philadelphia 1994, pp. 2059-2065.
- D. A. Brown, K. M. Herlihy and S. K. O'Shea, Kinetics of iron(III) chelation from polynuclear oxo-hydroxy aggregates by hydroxamic acids: Understanding ferritin iron (III) sequestration, Inorg. Chem. 38 (1999) 3198-3202; DOI: 10.1021/ic990158o.
- R. C. Hider, Z. D. Liu and S. Piyamongkol, Design and properties of 3-hydroxypyridin-4-one iron chelators with high Fe(3+) values, Transfus. Sci. 23 (2000) 201-209; DOI: 10.1016/S0955-3886(00)00090-4.
- E. Farkas, É. A. Enyedy and I. Fábián, New insight into the oxidation of Fe(II) by desferrioxamine B (DFB), Inorg. Chem. Commun. 6 (2003) 131-134; DOI: 10.1016/S1387-7003(02)00703-7.
- N. Gálvez, B. Ruiz, R. Cuesta, E. Colacio and J. M. Dominquez-Vera, Release of iron ferritin by aceto- and benzohydroxamic acids, Inorg. Chem. 44 (2005) 2706-2709; DOI: 10.1021/ic048840s.
- M. Porcu, N. Landis, S. Salis, M. Corda, P. Orru, E. Serra, B. Usai, G. Matta and R. Galanello, Effect of combined deferiprone and desferrioxamine iron chelating therapy in beta-thalassemia major end-stage heart failure, Eur. J. Heart Fail. 9 (2007) 320-322.
- F. Aucella, M. Vigilante, P. Scalzulli, P. Musto, M. Prencipe, G. L. Valente, M. Carotenuto and C. Stallone, Synergistic effect of desferrioxamine and recombinant erythropoietin on erythroid precursor proliferation in chronic renal failure, Nephrol. Dial. Transplant. 14 (1999) 1171-1175.
- N. T. V. Le and D. R. Richardson, Iron chelators with high antiproliferative activity up-regulate the expression of a growth inhibitory and metastasis suppressor gene: a link between iron metabolism and proliferation, Blood 104 (2004) 2967-2975; DOI: 10.1182/blood-2004-05-1866.
- D. R. Richardson and P. Ponka, Pyridoxal isonicotinoyl hydrazone and its analogs: Potential orally effective iron-chelating agents for the treatment of iron overload disease, J. Lab. Clin. Med. 131 (1998) 306-315; DOI: 10.1016/S0022-2143(98)90180-9.